- Home
- CAPT vs EDSA Comparison
CAPT vs EDSA Comparison
Compare CAPT & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAPT | EDSA |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | South Korea | Canada |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 12.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CAPT | EDSA |
|---|---|---|
| Price | $0.55 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 3.5M | 46.7K |
| Earning Date | 01-01-0001 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,389,944.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 84.70 | N/A |
| 52 Week Low | $0.30 | $1.23 |
| 52 Week High | $1.94 | $4.49 |
Technical Indicators
Market Signals| Indicator | CAPT | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 53.19 | 25.43 |
| Support Level | $0.49 | $1.41 |
| Resistance Level | $0.69 | $1.54 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 48.76 | 18.09 |
Price Performance
Historical ComparisonAbout CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.